# VOQUEZNA® (vonoprazan) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/vonoprazan

> The FDA approved VOQUEZNA® (vonoprazan), sponsored by Phathom Pharmaceuticals, Inc. (PHAT), on June 6, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is VOQUEZNA® (vonoprazan) FDA approved?

Yes. The FDA approved VOQUEZNA® (vonoprazan), sponsored by Phathom Pharmaceuticals, Inc. (PHAT), on June 6, 2025. SEC Form 8-K: "As referenced above, on June 6, 2025, the FDA has approved the Citizen Petition and communicated its intention to correct the Orange Book to recognize the proper 10 years of New Chemical Entity exclusivity for VOQUEZNA® (vonoprazan) tablets, extending through May 3, 2032." [Calendar and source filings](https://sec-api.dev/pdufa/vonoprazan)

Source: SEC Form 8-K, accession 0001193125-25-137094, https://www.sec.gov/Archives/edgar/data/1783183/000119312525137094/d941196d8k.htm (retrieved 2026-11-12). Last confirmed 2025-06-06. Cite: https://sec-api.dev/pdufa/vonoprazan#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | VOQUEZNA® (vonoprazan) |
| Codes |  |
| Sponsor | Phathom Pharmaceuticals, Inc. (PHAT) https://sec-api.dev/companies/phat/catalysts |
| Indications | erosive gastroesophageal reflux disease, or erosive gerd, [eosinophilic esophagitis](https://sec-api.dev/indications/eosinophilic-esophagitis), [Symptomatic Non-erosive Gastroesophageal Reflux Disease](https://sec-api.dev/indications/symptomatic-non-erosive-gastroesophageal-reflux-disease) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### February 7, 2023: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22215151_2024_Orig1s000OtherActionLtrs.pdf%22

### Sep 2023: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2025-03-06, last confirmed 2025-10-30.
- SEC Form 10-Q (accession 0001193125-25-257390): "In September 2023, we submitted an NDA seeking approval of vonoprazan as a once-daily treatment for heartburn symptoms associated with Non-Erosive GERD in adults." https://www.sec.gov/Archives/edgar/data/1783183/000119312525257390/phat-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-104548): "In September 2023, we submitted an NDA seeking approval of vonoprazan as a once-daily treatment for heartburn symptoms associated with Non-Erosive GERD in adults." https://www.sec.gov/Archives/edgar/data/1783183/000095017025104548/phat-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-061440): "In September 2023, we submitted an NDA seeking approval of vonoprazan as a once-daily treatment for heartburn symptoms associated with Non-Erosive GERD in adults." https://www.sec.gov/Archives/edgar/data/1783183/000095017025061440/phat-20250331.htm
- SEC Form 10-K (accession 0000950170-25-034183): "In September 2023, we submitted an NDA seeking approval of vonoprazan as a once-daily treatment for heartburn symptoms associated with Non-Erosive GERD in adults." https://www.sec.gov/Archives/edgar/data/1783183/000095017025034183/phat-20241231.htm

### Nov 2023: NDA/BLA submission

- Status: completed. Date confidence: month.
- First seen 2025-03-06, last confirmed 2025-03-06.
- SEC Form 10-K (accession 0000950170-25-034183): "In November 2023, we received FDA approval of vonoprazan, under the brand name VOQUEZNA, for the healing and maintenance of healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults, and in September 2023, we submitted an NDA seeking approval of vonoprazan as a once-daily treatment of heartburn associated with Non-Erosive GERD in adults." https://www.sec.gov/Archives/edgar/data/1783183/000095017025034183/phat-20241231.htm

### November 1, 2023: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: erosive gastroesophageal reflux disease, or Erosive GERD.
- First seen 2025-03-06, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA215151 ORIG-1 (Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated): submission_status AP, submission_status_date 20231101, review_priority STANDARD; sponsor_name PHATHOM; product VOQUEZNA (VONOPRAZAN FUMARATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215151%22
- SEC Form 10-Q (accession 0001193125-26-436961): "On November 1, 2023, the FDA approved the Company's NDA for VOQUEZNA 10 mg and 20 mg tablets for the treatment of erosive gastroesophageal reflux disease, or Erosive GERD." https://www.sec.gov/Archives/edgar/data/1783183/000119312526436961/phat-20260930.htm
- SEC Form 10-K (accession 0001193125-26-073379): "On October 27, 2023, the FDA approved the prior approval supplements to the Company's NDAs, for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK." https://www.sec.gov/Archives/edgar/data/1783183/000119312526073379/phat-20251231.htm
- SEC Form 10-K (accession 0001193125-26-073379): "Additionally, on November 1, 2023, the FDA approved the Company's NDA for VOQUEZNA tablets." https://www.sec.gov/Archives/edgar/data/1783183/000119312526073379/phat-20251231.htm
- SEC Form 10-K (accession 0001193125-26-073379): "Under the terms of the Revenue Interest Financing Agreement and Joinder Agreement, we received $100 million at the initial closing and received an additional $175 million in November 2023 following FDA approval of vonoprazan in its Erosive GERD indication." https://www.sec.gov/Archives/edgar/data/1783183/000119312526073379/phat-20251231.htm
- SEC Form 10-K (accession 0000950170-25-034183): "In November 2023, we received FDA approval of vonoprazan, under the brand name VOQUEZNA, for the healing and maintenance of healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults, and in September 2023, we submitted an NDA seeking approval of vonoprazan as a once-daily treatment of heartburn associated with Non-Erosive GERD in adults." https://www.sec.gov/Archives/edgar/data/1783183/000095017025034183/phat-20241231.htm
- SEC Form 10-K (accession 0000950170-25-034183): "73 we received $100 million at the initial closing and received an additional $175 million in November 2023 following FDA approval of vonoprazan in its Erosive GERD indication." https://www.sec.gov/Archives/edgar/data/1783183/000095017025034183/phat-20241231.htm
- SEC Form 10-Q (accession 0001193125-26-324867): "On November 1, 2023, the FDA approved the Company's NDA for VOQUEZNA 10mg and 20mg tablets for the treatment of erosive gastroesophageal reflux disease, or Erosive GERD." https://www.sec.gov/Archives/edgar/data/1783183/000119312526324867/phat-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-193946): "On October 27, 2023, the FDA approved the prior approval supplements to the Company's NDAs, for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK." https://www.sec.gov/Archives/edgar/data/1783183/000119312526193946/phat-20260331.htm
- SEC Form 10-Q (accession 0001193125-26-193946): "Additionally, on November 1, 2023, the FDA approved the Company's NDA for VOQUEZNA tablets." https://www.sec.gov/Archives/edgar/data/1783183/000119312526193946/phat-20260331.htm
- SEC Form 10-Q (accession 0001193125-25-257390): "On October 27, 2023, the FDA approved the prior approval supplements to the Company's NDAs, for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK." https://www.sec.gov/Archives/edgar/data/1783183/000119312525257390/phat-20250930.htm
- SEC Form 10-Q (accession 0001193125-25-257390): "Additionally, on November 1, 2023, the FDA approved the Company's NDA for VOQUEZNA tablets." https://www.sec.gov/Archives/edgar/data/1783183/000119312525257390/phat-20250930.htm

### July 17, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-03-06, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA218710 ORIG-1 (Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval): submission_status AP, submission_status_date 20240717, review_priority STANDARD; sponsor_name PHATHOM PHARMACEUTICALS INC; product VOQUEZNA (VONOPRAZAN FUMARATE)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218710%22
- SEC Form 10-Q (accession 0001193125-26-436961): "The royalty rate is subject to a step-down on net sales exceeding certain annual thresholds and when the Company received FDA approval for vonoprazan for an indication relating to the treatment of heartburn associated with Non-Erosive GERD, which occurred on July 17, 2024." https://www.sec.gov/Archives/edgar/data/1783183/000119312526436961/phat-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-324867): "The royalty rate is subject to a step-down on net sales exceeding certain annual thresholds and when the Company received FDA approval for vonoprazan for an indication relating to the treatment of heartburn associated with Non-Erosive GERD, which occurred on July 17, 2024." https://www.sec.gov/Archives/edgar/data/1783183/000119312526324867/phat-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-193946): "The royalty rate is subject to a step-down on net sales exceeding certain annual thresholds and when the Company received FDA approval for vonoprazan for an indication relating to the treatment of heartburn associated with Non-Erosive GERD, which occurred on July 17, 2024." https://www.sec.gov/Archives/edgar/data/1783183/000119312526193946/phat-20260331.htm
- SEC Form 10-K (accession 0001193125-26-073379): "The royalty rate is subject to a step-down on net sales exceeding certain annual thresholds and when the Company received FDA approval for vonoprazan for an indication relating to the treatment of heartburn associated with Non-Erosive GERD, which occurred on July 17, 2024." https://www.sec.gov/Archives/edgar/data/1783183/000119312526073379/phat-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-257390): "The royalty rate is subject to a step-down on net sales exceeding certain annual thresholds and when the Company received FDA approval for vonoprazan for an indication relating to the treatment of heartburn associated with Non-Erosive GERD, which occurred on July 17, 2024." https://www.sec.gov/Archives/edgar/data/1783183/000119312525257390/phat-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-104548): "The royalty rate is subject to a step-down on net sales exceeding certain annual thresholds and when the Company received FDA approval for vonoprazan for an indication relating to the treatment of heartburn associated with Non-Erosive GERD, which occurred on July 17, 2024." https://www.sec.gov/Archives/edgar/data/1783183/000095017025104548/phat-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-061440): "The royalty rate is subject to a step-down on net sales exceeding certain annual thresholds and when the Company received FDA approval for vonoprazan for an indication relating to the treatment of heartburn associated with Non-Erosive GERD, which occurred on July 17, 2024." https://www.sec.gov/Archives/edgar/data/1783183/000095017025061440/phat-20250331.htm
- SEC Form 10-K (accession 0000950170-25-034183): "Further, on July 17, 2024, the FDA approved VOQUEZNA 10 mg tablets for the relief of heartburn associated with Non-Erosive GERD and we launched vonoprazan in the U.S. for daily treatment of heartburn associated with Non-Erosive GERD in the third quarter of 2024." https://www.sec.gov/Archives/edgar/data/1783183/000095017025034183/phat-20241231.htm
- SEC Form 10-K (accession 0000950170-25-034183): "The royalty rate is subject to a step-down on net sales exceeding certain annual thresholds and when we received FDA approval for vonoprazan for an indication relating to the treatment of heartburn associated with Non-Erosive GERD, which occurred on July 17, 2024." https://www.sec.gov/Archives/edgar/data/1783183/000095017025034183/phat-20241231.htm
- SEC Form 10-K (accession 0000950170-25-034183): "The royalty rate is subject to a step-down on net sales exceeding certain annual thresholds and when the Company received FDA approval for vonoprazan for an indication relating to the treatment of heartburn associated with Non-Erosive GERD, which occurred on July 17, 2024." https://www.sec.gov/Archives/edgar/data/1783183/000095017025034183/phat-20241231.htm

### June 6, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-06-06, last confirmed 2025-06-06.
- SEC Form 8-K (accession 0001193125-25-137094): "As referenced above, on June 6, 2025, the FDA has approved the Citizen Petition and communicated its intention to correct the Orange Book to recognize the proper 10 years of New Chemical Entity exclusivity for VOQUEZNA® (vonoprazan) tablets, extending through May 3, 2032." https://www.sec.gov/Archives/edgar/data/1783183/000119312525137094/d941196d8k.htm
- SEC Form 8-K (accession 0001193125-25-137094): "On June 6, 2025, Phathom Pharmaceuticals, Inc. ("Phathom" or the "Company"), announced that the U.S. Food and Drug Administration ("FDA") approved the Company's Citizen Petition filed on December 11, 2024 (the "Citizen Petition")." https://www.sec.gov/Archives/edgar/data/1783183/000119312525137094/d941196d8k.htm

### Q4 2025: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2025-08-07, last confirmed 2025-08-07.
- SEC Form 10-Q (accession 0000950170-25-104548): "We plan to initiate our Phase 2 clinical trial of vonoprazan in eosinophilic esophagitis (EoE) trial during the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1783183/000095017025104548/phat-20250630.htm

### November 4, 2025: trial start

- Status: completed. Date confidence: exact. Stage: 2.
- First seen 2025-11-04, last confirmed 2025-11-04.
- SEC Form 8-K (accession 0001193125-25-263534): "On November 4, 2025, Phathom Pharmaceuticals, Inc. ("Phathom" or the "Company") announced the first patient has been dosed in its Phase 2 pHalcon EoE-201 clinical trial evaluating VOQUEZNA® (vonoprazan) tablets as an investigational treatment for eosinophilic esophagitis ("EoE") in adults." https://www.sec.gov/Archives/edgar/data/1783183/000119312525263534/d20656d8k.htm

### September 11, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Eosinophilic Esophagitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06851559 (A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-11 (ACTUAL); Lead Sponsor Phathom Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT06851559

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: eosinophilic esophagitis.
- First seen 2026-04-30, last confirmed 2026-11-16T22:20:01.192Z.
- SEC Form 8-K (accession 0001193125-26-278533): "Topline results are anticipated in the fourth quarter 2026." https://www.sec.gov/Archives/edgar/data/1783183/000119312526278533/d166684d8k.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-436959): "Phathom expects to report topline results during the fourth quarter 2026 for the" https://www.sec.gov/Archives/edgar/data/1783183/000119312526436959/d180192dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-324865): "Topline results from the 12-week blinded treatment portion of the trial are expected during the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1783183/000119312526324865/d114879dex991.htm
- SEC Form 10-Q (accession 0001193125-26-436961): "Topline results from the 12-week blinded treatment portion of the trial are expected to be reported during the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1783183/000119312526436961/phat-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-324867): "Topline results from the 12-week blinded treatment portion of the trial are expected during the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1783183/000119312526324867/phat-20260630.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-193945): "The Phase 2 pHalcon-EoE-201 trial evaluating VOQUEZNA in patients with eosinophilic esophagitis (EoE) is enrolling ahead of schedule with topline results now anticipated in late fourth quarter 2026 or early first quarter 2027." https://www.sec.gov/Archives/edgar/data/1783183/000119312526193945/d140332dex991.htm
- ClinicalTrials.gov: "NCT06851559 (A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-11 (ACTUAL); Lead Sponsor Phathom Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT06851559

### 2027: topline data readout

- Status: scheduled. Date confidence: year.
- First seen 2025-10-30, last confirmed 2026-02-26.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-073377): "Topline results are anticipated in 2027." https://www.sec.gov/Archives/edgar/data/1783183/000119312526073377/d119012dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-073377): "our development plans and potential timelines including our ability to report topline results from the pHalcon-EoE-201 trial in 2027" https://www.sec.gov/Archives/edgar/data/1783183/000119312526073377/d119012dex991.htm
- SEC Form 8-K (accession 0001193125-25-263534): "Topline primary and secondary results are anticipated to be available in 2027." https://www.sec.gov/Archives/edgar/data/1783183/000119312525263534/d20656d8k.htm
- SEC Form 10-K (accession 0001193125-26-073379): "We anticipate topline data from this trial in 2027." https://www.sec.gov/Archives/edgar/data/1783183/000119312526073379/phat-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-257382): "Topline results are anticipated in 2027." https://www.sec.gov/Archives/edgar/data/1783183/000119312525257382/d68071dex991.htm

### October 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Symptomatic Non-erosive Gastroesophageal Reflux Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07752407 (A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-20 (ESTIMATED); Lead Sponsor Phathom Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT07752407

### Q1 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Symptomatic Non-erosive Gastroesophageal Reflux Disease.
- First seen 2026-10-29, last confirmed 2026-11-16T22:20:01.192Z.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-436959): "The first subject has been dosed, and sites are currently enrolling across the U.S. Topline results are expected in the first quarter 2028." https://www.sec.gov/Archives/edgar/data/1783183/000119312526436959/d180192dex991.htm
- ClinicalTrials.gov: "NCT07752407 (A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-20 (ESTIMATED); Lead Sponsor Phathom Pharmaceuticals, Inc.." https://clinicaltrials.gov/study/NCT07752407

Calendar months: [October 2027](https://sec-api.dev/fda-calendar/2027-10)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/vonoprazan.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VOQUEZNA® (vonoprazan) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/vonoprazan

```bibtex
@misc{secapidev_pdufa_vonoprazan_20261116,
  title        = {VOQUEZNA® (vonoprazan) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/vonoprazan}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_vonoprazan_20261116","title":"VOQUEZNA® (vonoprazan) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/vonoprazan","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
